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Abstract
Background: In patients with COPD progressive dyspnoea leads to a sedentary lifestyle. To date, no studies exist
investigating the effects of Nordic Walking in patients with COPD. Therefore, the aim was to determine the
feasibility of Nordic Walking in COPD patients at different disease stages. Furthermore we aimed to determine the
short- and long-term effects of Nordic Walking on COPD patients’ daily physical activity pattern as well as on
patients exercise capacity.
Methods: Sixty COPD patients were randomised to either Nordic Walking or to a control group. Patients of the
Nordic Walking group (n = 30; age: 62 ± 9 years; FEV1: 48 ± 19% predicted) underwent a three-month outdoor
Nordic Walking exercise program consisting of one hour walking at 75% of their initial maximum heart rate three
times per week, whereas controls had no exercise intervention. Primary endpoint: daily physical activities (measured
by a validated tri-axial accelerometer); secondary endpoint: functional exercise capacity (measured by the six-minute
walking distance; 6MWD). Assessment time points in both groups: baseline, after three, six and nine months.
Results: After three month training period, in the Nordic Walking group time spent walking and standing as well
as intensity of walking increased (Δ walking time: +14.9 ± 1.9 min/day; Δ standing time: +129 ± 26 min/day;
Δ movement intensity: +0.40 ± 0.14 m/s
2) while time spent sitting decreased (Δ sitting time: -128 ± 15 min/day)
compared to baseline (all: p < 0.01) as well as compared to controls (all: p < 0.01). Furthermore, 6MWD significantly
increased compared to baseline (Δ 6MWD: +79 ± 28 meters) as well as compared to controls (both: p < 0.01).
These significant improvements were sustained six and nine months after baseline. In contrast, controls showed
unchanged daily physical activities and 6MWD compared to baseline for all time points.
Conclusions: Nordic Walking is a feasible, simple and effective physical training modality in COPD. In addition,
Nordic Walking has proven to positively impact the daily physical activity pattern of COPD patients under short-
and long-term observation.
Clinical trial registration: Nordic Walking improves daily physical activities in COPD: a randomised controlled
trial - ISRCTN31525632
Introduction
Despite optimal pulmonary drug treatment, patients
with chronic obstructive pulmonary disease (COPD) fre-
q u e n t l ye x p e r i e n c ed y s p n o e aa n df a t i g u ed u r i n ge v e r y -
day life, which may result in daily physical inactivity [1].
Indeed, COPD patients are significantly less active com-
pared to healthy controls, spending most of the day
sitting or lying [2,3]. Moreover, low daily physical activ-
ity levels decrease during acute exacerbation, followed
by only partial recovery [4]. This ‘downward disease
spiral’ is one of the major challenges in the long term
management of COPD [5]. In fact, higher dyspnea
symptoms have been related to worse exercise perfor-
mance, health status and poor survival in COPD [6,7].
Moreover, lower levels of physical activity in daily life may
contribute to a higher risk of hospital readmission [8] * Correspondence: marie.breyer@gmx.at
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such as from a sedentary to a more active lifestyle,
has been set as one of the key goals of pulmonary rehabili-
tation [10].
Comprehensive pulmonary rehabilitation programs
improve COPD patients’ peripheral muscle function,
functional exercise capacity, daily symptoms of dys-
pnoea, fatigue, anxiety and depression, and health status
[10]. However, most of the studies lack to transfer these
achievements into long-term observation [11], indicating
that an improvement in functional exercise capacity
does not automatically turn into a more active lifestyle.
The effects of pulmonary rehabilitation on daily physical
activity level in COPD have been scarcely studied in
non-randomised and/or non-controlled trial designs
with no or modest effects [12-14].
We hypothesised that physical training modalities
copying everyday-life activities might translate better
into patients’ physical performance status [15]. Nordic
Walking, which involves, by definition, walking with
specially designed poles, proved to be a safe and effec-
tive physical training method in cardiac rehabilitation
[16]. Moreover, Nordic Walking had been revealed to
enhance oxygen uptake and to consecutively increase
caloric expenditure on the treadmill as well as in field
testing in healthy [17-19].
To date, no studies are available investigating the
effects of Nordic Walking in COPD. Therefore our pri-
mary aim was to determine the feasibility of Nordic
Walking in COPD patients at different disease stages,
more precisely if training walking speed can achieve pre-
set heart rate directed training goals. Furthermore we
aimed to determine the long-term effect of Nordic
Walking on patients’ daily physical activity pattern.
Finally, we investigated the effects of Nordic Walking on
COPD patients’ functional exercise capacity, exercise
induced dyspnoea, mood status, and health-related qual-
ity of life in short- and long-term observation.
Methods
Design
The present study was designed as a prospective, rando-
mised, controlled trial. Local ethics committee approved
the study and all patients gave written informed consent
before participating in the study. The study is registered
in the ISRCTN Register (ISRCTN31525632 - http://
www.controlled-trials.com/ISRCTN31525632). Some of
the baseline data have been presented in a previous
study [3]. All patients were retired at time of inclusion
or on sick leave. Randomisation to either the Nordic
Walking or the control group was done by a computer-
generated algorithm maintained by SPSS version 15.01.
The present study was the first to investigate the effect
of Nordic Walking on the physical activity of COPD
patients. Therefore, we were unable to reliably estimate
the effect size and variances prior to the study. Hence,
for both groups we chose a large sample size of n = 28,
which was judged to allow detection of relevant
between-group differences in a two-factorial ANOVA
with repeated measurements.
Participants
COPD patients were initially screened from March 2006
until March 2007. Exclusion criteria: self reported
exacerbation < twelve weeks, myocardial infarction < six
month, cardiac arrhythmias > Lown IIIb, or walking dis-
turbances due to muscle or bone diseases. All partici-
pants attended one educational session/week [20] on
pulmonary pathophysiology, the management of breath-
lessness and exacerbations, the clearance of pulmonary
secretions, smoking cessation, medication and nutrition.
Nordic Walking group
Patients performed maximal exercise testing to obtain
maximum heart rate (HR). The preset goal for training
efficiency was set at 75% of the initial maximum HR,
three times a week according to international recom-
mendations [10]. Patients were matched for initially
obtained maximum HR during maximal exercise testing
to ascertain similar walking speeds. Patients received a
two-hour instruction by a professional Nordic Walking
instructor. None of the patients had any difficulties in
performing Nordic Walking adequately. HR was moni-
tored by a pulse watch (HRT 1100, Innovit GmBH; Fre-
chen, Germany), and oxygen saturation was measured
by a portable pulse oximeter (OxiPrint, Vivisol; Wiscon-
sin, USA). Patients on long term oxygen therapy
(LTOT) were using their LTOT during the intervention
as recommended [10]. During training all patients were
supervised as well as data were recorded by medical
staff and walking speed was, if necessary, adapted to
bearable dyspnoea and optimal oxygen saturation.
Nordic Walking
The International Nordic Walking Federation (INWA) is
the official worldwide international federation promoting
Nordic Walking and was founded in Finland in 2000
http://inwa-nordicwalking.com. The principle is that
walking with the poles increases muscle use and walking
speed, both of them increasing VO2 and lactate [21].
Nordic Walking is mostly performed outdoors and due
to the specially constructed poles Nordic Walking can
be performed independent of ground quality (asphalt,
meadow; additional file 1.). The type of walking poles
used in the present study was Power Poles (LEKI; Ham-
burg, Germany). Power Poles are built of light-weight
aluminium and weigh approximately 440 grams each.
The body of the pole is constructed in such a way that
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then springs back to its normal length through the
push-off phase of the walking stride. Additionally, the
body of the poles are made to be adjustable to the
height of the user. The tip of the pole is made of 100%
rubber and is designed to be shock absorbent and slip
resistant. The handles of the Power Poles are anatomi-
cally designed to fit the hand. The current costs for
LEKI power poles currently ranges (April 2010) between
25. - 80. - EURO.
Primary endpoint
Daily physical activities
Physical activity is defined as any bodily movement pro-
duced by skeletal muscles [22], such as standing or
walking that result in energy expenditure beyond the
resting expenditure. A tri-axial accelerometer (DynaPort
Activity Monitor; McRoberts BV; Den Haag, the Nether-
lands) was used to assess the daily physical activities of
the COPD patients. The DynaPort consists of a small
lightweight box enclosed in a belt that is worn around
t h ew a i s ta n dal e gs e n s o rt h a ti sw o r na r o u n dt h el e f t
upper leg. Multi-axial devices are able to detect motion
in more than one plane of movement and therefore
time spent walking, standing, sitting or lying, as well as
the movement intensity, which is given in meters
divided by seconds squared (m/s
2), during walking can
precisely be measured. The DynaPort is validated in
patients with COPD [23,24]. Technical specifications of
the activity monitor are described elsewhere [24]. Data
were collected during three consecutive week days for
12-hours after the patient woke up [25]. No data were
recorded during sleep, weekend or Nordic Walking. The
average of the three recorded assessment days was used
for analysis. All subjects were carefully instructed on
how to position the device, and they received a manual
with clear figures and instructions. In addition, patients
had to fill in a daily checklist to verify if the day had
been representative. Daily physical activities were
assessed at baseline, after three, six, and nine month in
both groups.
Secondary endpoints
Functional exercise capacity, exercise-induced dyspnoea,
mood status, and health-related quality of life
Functional exercise capacity was assessed using the six-
minute walking test (6MWT) [26] expressed as a per-
centage of the predicted distance [27]. Perceived dys-
pnoea after the 6MWT was recorded using the modified
BORG dyspnoea scale [28]. The assessment of mood
status was performed using the hospital anxiety and
depression scale (HADS) [29] with a cut-off ≥7p o i n t s
for each scale to identify the presence of symptoms of
anxiety and/or depression. Generic quality of life was
evaluated using the Medical Outcomes Study 36-item
short form (SF-36) [30]. Scores for the Physical Compo-
nent Summary (PCS) and the Mental Component
Summary (MCS) range from 0 to 100, with scores
>50 points representing better generic quality of life.
Additional variables
Lung function data were collected using standardised
spirometry [31] (Sensor Medics Vmax 22, Viasys
Healthcare; California, USA). Airflow limitation was
classified according to the latest ERS/ATS guidelines [1].
Additionally, patients’ height and weight were measured,
body mass index was calculated and relevant co-morbid-
ities, such as cardiovascular disease, and the use of
LTOT were recorded.
Statistical analyses
Categorical variables were described as frequencies.
Continuous variables were tested for normality by a nor-
mal plot and presented as mean ± standard deviation
(SD). Evaluation of differences in mean levels for base-
line characteristics between the Nordic Walking and the
control group was done using one-way ANOVA.
Between group and within group differences in outcome
parameters were tested using ANOVA accounting for
repeated-measurements. The sphericity assumption was
assessed by Mauchly’s test, and p values were corrected
by the Greenhouse-Geisser method, if required. All
analyses were performed using SPSS version 15.01.
A p-value of ≤ 0.05 was considered to be significant.
Results
In total 60 COPD patients completed the study and
were included into the analyses. A diagram of partici-
pant flow is shown in Figure 1. The baseline characteris-
tics of both groups are shown in Table 1. No statistical
significances were found between the two groups at
baseline.
Primary endpoint
Feasibility of Nordic Walking
All patients achieved the preset goal for maximum HR
to ensure training efficiency (> 75% of the initial maxi-
mum HR), even though walking at different speed levels
according to the severity of COPD. None of the patients
had any difficulties in performing Nordic Walking ade-
quately. It seemed to be an advantage over cycling that
walking speed could be adapted to dyspnoea levels with-
out missing the preset HR goal [32]. No (serious)
adverse events were reported.
Daily physical activities
After the three-month training period, movement inten-
sity increased in the Nordic Walking group compared to
their baseline (Δ movement intensity: +0.40 ± 0.14 m/s
2,
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Page 3 of 9p < 0.01) as well as compared to controls (p <0 . 0 1 ;F i g -
ure 2), while controls remained unchanged (p =0 . 3 8 5 ) .
Movement intensity increased in the six-month un-coa-
ched observation period in Nordic Walking patients
compared to baseline (Δ movement intensity: +0.25 ±
0.09 m/s
2, p < 0.01) and compared to controls (p <0 . 0 1 ) .
Controls movement intensity slowly declined and was
below their baseline levels after nine month (p < 0.01).
Training increased the walking and standing time of
the Nordic Walking group significantly (Δ walking time:
+14.9 ± 1.9 min/day, p < 0.01; Δ standing time: +129 ±
26 min/day, p < 0.01) at the expense of their sitting
time (Δ sitting time: -128 ± 15 min/day, p < 0.01). Same
results were found compared to controls (walking: p =
0.034; sitting: p = 0.014; Figure 3). Walking time
remained increased (six month: Δ walking time: +12.7 ±
1.8 min/day, p =0 . 0 2 4 ;n i n em o n t h :Δ walking time:
+9.2 ± 2.9 min/day, p = 0.036), and sitting time
remained decreased (six month: Δ sitting time: -120 ±
32 min/day, p =0 . 0 1 6 ;n i n em o n t h :Δ sitting time: -101
± 36 min/day, p = 0.032) compared to baseline as well
as compared to controls at follow up (six month: p <
0.05; nine month: p < 0.01). Finally, initial increase of
standing time was preserved in the Nordic Walking
Assessed for eligibility
n=98
Excluded
n=33
Not meeting inclusion criteria
(Unstable COPD, n=20;
Unstable cardiac disease, n=8;
Symptomatic osteoporosis, n=3; 
Stroke, n=2)
Analysed
n=30
Discontinued intervention
n=2
due to acute exacerbation
Allocated to intervention group
n=32
Lost to follow-up
n=3
Allocated to control group
n=33
Allocation
3 month intervention
Analysis
Follow-Up
6 month
Enrollment
n=65
Randomised
n=65
Analysed
n=30
Recruitment of patients
Outpatient clinic: n=53
Local chest physicians: n=34
Advertisement: n=11
Figure 1 Patient flow diagram.
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time: +133 ± 14 min/day, p < 0.01; nine month: Δ stand-
ing time: +105 ± 4 min/day, p < 0.01) as well as com-
pared to controls (six month, nine month: both: p <
0.05). Controls did not show any significant change in
their daily physical activities at any time point compared
to baseline.
Secondary endpoints
Functional exercise capacity
Training increased the 6MWD in the Nordic Walking
group compared to baseline (Δ 6MWD: +79 ± 28 meters;
p < 0.01; Figure 4) and controls (p < 0.01). This increase
lasted over the un-coached observation period (six
month: Δ 6MWD: +70 ± 16 meters; nine month:
Table 1 Baseline characteristics
total (n = 60), mean (±SD) Nordic Walking group (n = 30) control group (n = 30)
age, years 60.3 (8.45) 61.9 (8.87) 59.0 (8.02)
male sex, % 45 47 43
LTOT, n (%) 5 (8.3) 2 (3.3) 3 (5.0)
FEV1, % predicted 46.3 (17.6) 48.1 (19.1) 47.1 (16.3)
FEV1/FVC, % predicted 44.9 (10.7) 45.2 (11.6) 45.3 (10.5)
GOLD II, III, IV, (%) 27 (45), 14 (23), 19 (32) 13 (43), 7 (24), 10 (33) 14 (47), 7 (23), 9 (30)
BMI, kg/m
2 26.2 (4.6) 25.9 (4.5) 26.5 (4.9)
6MWD, m 446 (140) 461 (154) 436 (128)
6MWD, % predicted 66.9 (19.6) 66.4 (22.1) 67.3 (17.3)
peak load, watts - 68.0 (24.1) -
peak load, % predicted - 54.6 (14.3) -
BORG score, points 4.3 (2.1) 4.4 (2.2) 3.9 (1.9)
HADS anxiety, ≥7 points 9.7 (3.8; n = 32) 8.8 (2.4; n = 15) 10.5 (3.6; n = 17)
HADS depression, ≥7 points 10.7 (3.2; n = 27) 9.9 (3.2; n = 12) 11.3 (3.1; n = 15)
SF 36 PCS, <50 points 32.0 (6.13; n = 53) 32.2 (6.50; n = 28) 31.7 (5.79; n = 25)
MCS, <50 points 40.9 (8.59; n = 30) 42.8 (7.41; n = 14) 39.2 (9.40; n = 16)
daily physical activities
movement intensity, m/s
2 1.55 (0.39) 1.59 (0.47) 1.50 (0.29)
walking, min/day 44.5 (35.6) 46.7 (35.2) 42.3 (36.5)
standing, min/day 218 (138) 215 (182) 222 (169)
sitting, min/day 348 (200) 334 (208) 362 (195)
lying, min/day 106 (118) 123 (138) 88.7 (91.5)
SD, standard deviation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index; 6MWD, six-minute walking distance; BORG,
BORG dyspnoea score after 6MWT; HADS, Hospital Anxiety and Depression Scale; SF 36, Short Form 36; PCS, Physical Component Score; MCS, Mental Component
Score; min/day, minutes per day.
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Figure 2 Movement intensity of COPD patients of intervention and control group over time. Statistical comparisons within groups: * p <0 . 0 1
compared to baseline. Statistical comparison between groups (intervention vs. control): † p < 0.01 at all times. (Whiskers represent SD).
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p < 0.01) and was different compared to controls (six
month: p = 0.01; nine month: p =0 . 0 1 3 ) .C o n t r o l s
showed a decrease in their 6MWD after six (p = 0.036)
and nine months (p < 0.01) compared to baseline.
Exercise-induced dyspnoea
Training improved the BORG dyspnoea score in the
Nordic Walking compared to baseline (p < 0.01; Table
2) and remained decreased after six and nine months
(both: p <0 . 0 1 ) .I nt h ec o n t r o l s ,t h eB O R Gd y s p n o e a
score remained unchanged after three (p = 0.712), six
(p = 0.202) and nine months (p = 0.178) compared to
baseline.
Mood status
According to baseline HADS, 32 patients had symptoms
of anxiety (≥7 points) and 27 patients had symptoms of
depression (≥7 points). HADS in the Nordic Walking
group decreased compared to baseline and to controls
(both: p < 0.01) after three month training and remained
decreased after six and nine months (all: p <0 . 0 1 )
whereas controls did not change their HADS after three
(p =0 . 1 0 4 ,p = 0.242), six (p =0 . 2 1 3 ,p = 0.253), and
nine months (p = 0.190, p = 0.260) compared to
baseline.
Health-related quality of life
Generic quality of life wasi m p a i r e d( <5 0p o i n t s )
according to the baseline SF-36 PCS and MCS, respec-
tively in 53 and 30 patients. The Nordic Walking group
increased their PCS points compared to baseline and
controls (both: p < 0.01) and PCS points remained
increased after six and nine months (all: p < 0.01; except
compared to controls after nine month: p < 0.05).
daily physical activities
0 200 400 600 800
9 month
6 month
3 month
control group baseline
9 month
6 month
3 month
intervention group baseline
walking
standing
sitting
lying
minutes/day
Figure 3 Daily physical activities of COPD patients of intervention and control group over time.
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Figure 4 Six-minute walking distance of COPD patients of intervention and control group over time. Statistical comparisons within
groups: * p < 0.01 compared to baseline; † p < 0.05 compared to baseline; statistical comparison between groups (intervention vs. control):
‡ p < 0.01 at all times. (Whiskers represent SD).
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(p = 0.989), six (p = 0.763), and nine months (p =
0.698) compared to baseline. The MCS remained
unchanged in both groups at any time points.
Discussion
Nordic Walking has proven to be a simple, safe, and
effective physical training modality for patients with
COPD. Indeed, this is the first study demonstrating that
Nordic Walking is feasible in patients with COPD and
can improve COPD patients’ daily physical activity
levels. In addition to the positive short-term effects of
Nordic Walking on the physical exercise performance
and daily symptoms of COPD patients, Nordic Walking
created a long-term effect on the training results even
after an un-coached observation period of six months.
COPD patients are a target group for exercise-based
rehabilitation as they spend most of their time sitting or
lying compared to healthy subjects [23]. In fact, even
COPD patients at GOLD stage II significantly limit their
daily physical activities compared to patients with
chronic bronchitis (former GOLD stage 0) [33]. The
efficacy of pulmonary rehabilitation programs on func-
tional exercise capacity and oxygen uptake capacity are
of proven evidence and have led to recommendation of
pulmonary rehabilitation for patients with chronic pul-
monary diseases in international guidelines [10]. Unfor-
tunately, access to pulmonary rehabilitation programs
are limited and in most countries underfunded. Nordic
Walking could provide an alternative, cheap and easy
accessible physical training modality. Another key goal
of pulmonary rehabilitation is to create long-lasting
health effects by changing patients’ lifestyle. However, in
COPD patients long-term effects of rehabilitation
addressed in few studies have shown no or modest suc-
cess [12-14]. We hypothesised that those physical train-
ing modalities, which imitate everyday life movements,
might lead to long-term improvement of daily physical
activities.
Nordic Walking increases exercise intensity of walking
due to the use of the typical Nordic Walking poles [17].
It enhances maximum oxygen consumption and heart
rate by an average of 20% compared to walking without
poles in healthy subjects [17,18]. The use of these poles
while walking implies an additional motion that leads to
larger oxygen consumption as well as to an increase in
heart rate [17,18]. In cardiac rehabilitation, Nordic
Walking has proven to be safe and effective [16].
To the authors’ best knowledge, there have been no
studies of Nordic Walking in COPD so far. The aims of
the study were to test whether Nordic Walking is feasi-
ble in terms of reaching the preset HR directed training
goal while controlling for dyspnoea and oxygen satura-
tion and whether training results in a significant
improve in functional exercise capacity. Indeed, all
COPD patients had no difficulties to perform Nordic
Walking within the preset aerobic training level
throughout the whole session, even patients on long
term oxygen. Nordic Walking was effective in alleviation
of dyspnoea, increased health related quality of life and
functional exercise capacity after three month according
to recommendations [10]. In contrast to other studies
[11], the three-month results were maintained after an
un-coached observation period of six months suggesting
that Nordic Walking creates not only a short-, but also
a long-term training effect in COPD patients. After nine
month of follow-up 63% of the COPD patients have
adopted Nordic Walking as regular physical exercise.
Table 2 Differences of exercise-induced dyspnoea, mood status, and health-related quality of life of COPD patients of
Nordic Walking and control group over time
baseline; mean (± SD) three month six month nine month
n = 30/group NW group control group NW group control
group
NW group control
group
NW group control
group
6MWD, meters 461 (154) 436 (128) 540*‡ (159) 442 (133) 531*‡ (142) 428† (138) 519*§ (160) 422* (130)
BORG, points 4.4 (2.2) 3.9 (1.9) 3.43* (1.76) 3.72 (1.53) 3.63* (1.79) 4.23 (1.89) 3.70* (1.60) 4.32 (1.92)
HADS, anxiety, ≥7
points
(n = 32)
8.8 (2.4; n = 15) 10.5 (3.6; n = 17) 6.6 *‡ (2.3) 10.2 (3.6) 7.3*‡ (2.1) 10.5 (3.8) 7.6*‡ (1.9) 10.9 (3.6)
depression, ≥7
points
(n = 27)
9.9 (3.2; n = 12) 11.3 (3.1; n = 15) 6.3*‡ (3.0) 11.6 (3.2) 6.8*‡ (3.0) 11.3 (3.3) 7.9*‡ (3.1) 11.7 (3.4)
SF 36 PCS, <50 points
(n = 53)
32.2 (6.50; n =
28)
31.7 (5.79; n =
25)
42.5*‡
(9.62)
32.7 (6.39) 44.1*‡
(8.12)
30.8 (7.40) 43.6*§
(9.52)
29.9 (6.89)
MCS, <50 points
(n = 30)
42.8 (7.41; n =
14)
39.2 (9.40; n =
16)
47.2 (10.7) 41.53 (12.8) 47.4 (8.91) 40.7 (9.36) 46.3 (9.27) 38.7 (8.71)
6MWD, six minute walking distance; BORG, BORG dyspnoea score after 6MWT; HADS, Hospital Anxiety and Depression Scale; SF 36, Short Form 36; PCS, Physical
Component Score; MCS, Mental Component Score; NW, Nordic Walking.
Statistical comparisons within groups: * p < 0.01 compared to baseline. † p < 0.05 compared to baseline.
Statistical comparison between groups (Nordic Walking vs. control): ‡ p < 0.01. § p < 0.05.
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long-term (six month) effects of pulmonary rehabilita-
tion on the daily physical activity pattern of COPD
patients found modest effects even in the long-term pro-
gram [14]. The maintained increase in daily physical
activities in our COPD patients might be due to the
type of training method used, a modified everyday
movement, walking, which resulted in a transfer into
patients’ daily life.
Besides physical symptoms, patients with COPD also
experience a higher psychological distress, especially
symptoms of anxiety and depression, compared to
healthy subjects [34]. Nordic Walking improved COPD
patients’ mood status, as symptoms of anxiety and
depression decreased after the three-month training per-
iod and lasted throughout the long-term observation. In
fact, symptoms of anxiety and depression in patients
with COPD are risks factors for re-hospitalisation, and
co-morbid depression is associated with poorer survival
in COPD [35]. Therefore, the relevant objective of pul-
monary rehabilitation to relief psychosocial burden [10]
seems to be achieved by Nordic Walking.
Methodological considerations
The results might be biased by the selection of very moti-
vated patients. However, motivation is required in rehabi-
litation in order to achieve the fullest benefits from
rehabilitation [10]. The low number of drop-outs in the
present study might be a signal towards this direction.
On the other hand the cheap technical equipment and
the independence from specific locations might open an
effective training method to a large number of COPD
patients. Our patients felt very encouraged by the dis-
tances they walked outside and finally were empowered
to leave their homes on their own which might not have
been the case in all patients. Furthermore, to gain more
insight into the physiological effects of Nordic Walking
further studies are needed to investigate e.g. the effects of
Nordic Walking on muscle force/weakness.
Conclusions
A three-month supervised Nordic Walking training pro-
gram has proven to be a safe training method to
increase the daily physical activity levels in clinically
stable outpatients with COPD. Beyond that, Nordic
Walking had a long-term effect on the patients’ daily
physical activity pattern and a reduction in patients’
daily symptoms.
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